Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Medicare Agency Suspends Advance Payment Program Loans For DME Suppliers, Physicians

Executive Summary

An advanced payment loan program supported by the CMS for durable medical equipment suppliers and health care providers during the COVID-19 pandemic was suspended by the agency on 26 April.

You may also be interested in...



Latest Coronavirus Bill Passage Adds $100Bn To National Testing Effort

With US House passage of a $484bn coronavirus relief package late on 23 April, Congress has allocated another substantial chunk of funding to support nationwide COVID-19 testing. President Trump signed the bill midday on 24 April.

COVID-19: CMS Approves $34Bn For DME Suppliers, Providers Via Accelerated, Advance Pay Programs

The US Medicare agency on 7 April said it delivered $34bn to suppliers of durable medical equipment and other providers fighting COVID-19 via an accelerated payment program.

Unpacking The $2.2Tn Stimulus Act: Boosts To Medtech And Diagnostics To Fight Coronavirus

A $2.2tn coronavirus stimulus package signed into law by President Trump on 27 March will distribute billions of dollars to federal agencies – including the FDA, the CDC and the FEMA – to hasten approvals of new diagnostics, medical ventilators, respirators and other medtech supplies, conduct more testing of potential COVID-19 patients, and quickly distribute medical supplies where needed most.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel